Longeveron Inc. (NASDAQ:LGVN) Shares Shorted: Short Interest Up 114.7% in October

Longeveron Inc. (NASDAQ:LGVN – Get Free Report) saw a significant growth in short interest in the month of October. As of October 30th, there was short interest totaling 157,139 shares, a growth of 114.7% from the October 15th total of 73,177 shares. Based on an average daily volume of 72,097 shares, the days-to-cover ratio is currently 2.2 days. Approximately 5.3% of the company’s shares are short sold.

Longeveron Price Performance

Shares of LGVN stock traded down $0.18 on Monday, hitting $2.31. The stock had a trading volume of 21,659 shares, compared to its average volume of 205,689. The firm has a market capitalization of $7.38 million, a P/E ratio of -0.29 and a beta of -0.09. Longeveron has a 1 year low of $1.31 and a 1 year high of $12.30. The company’s 50 day moving average price is $2.92 and its 200-day moving average price is $6.44.

Longeveron (NASDAQ:LGVN – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($1.91) EPS for the quarter, missing analysts’ consensus estimates of ($1.70) by ($0.21). Longeveron had a negative net margin of 1,921.72% and a negative return on equity of 243.26%. The firm had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.80 million. On average, equities analysts forecast that Longeveron will post -7.20 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Longeveron stock. ADAR1 Capital Management LLC acquired a new stake in Longeveron Inc. (NASDAQ:LGVN – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned approximately 0.86% of Longeveron as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 10.01% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Weiss Ratings cut Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Wall Street Zen downgraded Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Longeveron currently has a consensus rating of “Hold” and an average target price of $80.00.

View Our Latest Report on LGVN

Longeveron Company Profile

(Get Free Report)

Longeveron Inc. is a clinical-stage biotechnology company based in Miami, Florida, developing cell-based therapies for serious and age-related conditions. Its research focuses on medicinal signaling cells, a type of adult stem cell that may influence the body’s repair and immune responses. The company’s lead product candidate, Lomecel-B, is an investigational therapy made from donated bone marrow cells. Longeveron has studied it for conditions including hypoplastic left heart syndrome, Alzheimer’s disease and aging-related frailty.

Read More

Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.